BioAtla heads for Nasdaq on Wednesday following $189M IPO, going public with its pH-detecting cancer treatments

Yet another biotech is making its public debut Wednesday, and this one comes just a few months after a $72.5 million Series D round.

BioAtla becomes 2020’s latest industry IPO, having raised an upsized $189 million. Shares priced at $18 apiece, and with the biotech originally estimating $136.4 million in its S-1, BioAtla ended up raising about 38.6% more than planned. The newly-public company will trade under the ticker $BCAB once it officially hits the Nasdaq on Wednesday.